Clinical Trials
Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") announced positive preliminary results from a Phase I study of HDM2005, an...
September 08, 2025 | News
One-year SALWEEN results demonstrate robust efficacy, extended durability and consistent safety in patients with polypoidal choroidal vasculopathy (PCV),...
September 08, 2025 | News
Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and reducing study build timeline by up to 50% compared to ...
September 05, 2025 | News
Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study eva...
September 03, 2025 | News
Approximately 800 children aged 12 months to 12 years in Korea and abroad, aiming for completion by 2027 Rising demand for 2-dose regimen as internation...
September 03, 2025 | News
Bon Natural Life Limited , a leading bio-ingredient solution provider in the natural, health and personal care industry, announced a groundbreaking identif...
September 03, 2025 | News
AstraZeneca announced positive full results from the BaxHTN Phase III trial, showing that baxdrostat, a first-in-class aldosterone synthase inhibitor, achi...
September 02, 2025 | News
AMI Pharm's 'AYP-101' Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success 'AYP-101,' a Promising Nonsurgical Solution, H...
September 02, 2025 | News
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 – – ...
September 02, 2025 | News
Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet form...
August 28, 2025 | News
Leading U.S. stem cell banking and cellular therapeutic manufacturer Hope Biosciences announces the U.S. Food and Drug Administration (FDA) has g...
August 28, 2025 | News
Akeso Inc. announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibod...
August 26, 2025 | News
Nanjing Leads Biolabs Co., Ltd. announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following...
August 26, 2025 | News
Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of m...
August 26, 2025 | News
Most Read
Bio Jobs
News
Editor Picks